Suki, a company offering AI voice solutions to healthcare companies, has secured $70 million in Series D funding, it announced Thursday. The financing will help the company build new products.

The conundrum of American health care has become all too familiar: While spending outpaces other high-income countries, our quality of care often lags our peers – demonstrating no real ...

WebMD Ignite, a division of WebMD, unveiled a new solution on Thursday to help health plans administer care management programs. Newark, New Jersey-based WebMD provides health information services ...

The 2024 election is nearing the corner and has major implications for the healthcare industry, from abortion to drug pricing. During the Reuters Total Health Conference held in Chicago on Tuesday ...

The healthcare industry is on the cusp of a transformation similar to that witnessed by the banking industry 15 to 20 years ago. Like healthcare, banking is a very personal yet highly regulated ...

Bipartisan Congressional scrutiny has shone a harsh spotlight on the many tactics used by pharmacy benefit managers (PBMs) and Big Pharma that contribute to the sky high costs of prescription ...

Shortly after releasing a scathing interim report in July that revealed how three players dominate the pharmacy benefit manager market and raise drug costs for patients, the Federal Trade ...

Neuroscience drug developer Lundbeck is expanding its scope to epilepsy via the $2.6 billion acquisition of Longboard Pharmaceuticals, a company whose lead asset is in late-stage clinical ...

Johnson & Johnson stopped short of implementing its proposal to alter the way two drugs are paid for under the 340B drug discount program, but the drugmaker made it clear it still wants changes. In ...

The fee-for-service (FFS) payment model that has been the norm in healthcare for decades may finally be on its way out, with many physicians and hospital leaders leaning into value-based care (VBC).

Asthma patients have many drug options, but many patients find these choices either inconvenient or inadequate for severe cases of the chronic respiratory condition. Upstream Bio is pursuing a ...